ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 10,796 Shares

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Jaume Pons sold 10,796 shares of the business's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $1.58, for a total transaction of $17,057.68. Following the sale, the insider now directly owns 580,714 shares in the company, valued at approximately $917,528.12. The trade was a 1.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

ALX Oncology Stock Performance

NASDAQ ALXO traded down $0.11 during trading on Thursday, hitting $1.56. 759,703 shares of the company's stock traded hands, compared to its average volume of 830,562. The stock has a market capitalization of $82.28 million, a price-to-earnings ratio of -0.52 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The business has a 50 day moving average of $1.52 and a 200-day moving average of $2.90. ALX Oncology Holdings Inc. has a 12-month low of $1.19 and a 12-month high of $17.83.

Analyst Upgrades and Downgrades

ALXO has been the subject of several recent research reports. HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of ALX Oncology in a research note on Wednesday, December 18th. Jefferies Financial Group downgraded shares of ALX Oncology from a "buy" rating to a "hold" rating and decreased their target price for the company from $12.00 to $2.00 in a research report on Thursday, December 19th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a report on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, ALX Oncology has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds have recently bought and sold shares of ALXO. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock worth $39,000 after acquiring an additional 5,200 shares in the last quarter. Rhumbline Advisers raised its position in ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company's stock worth $333,000 after purchasing an additional 5,360 shares during the period. AQR Capital Management LLC lifted its stake in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock worth $109,000 after purchasing an additional 6,080 shares during the last quarter. SG Americas Securities LLC lifted its stake in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock worth $50,000 after purchasing an additional 6,888 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in ALX Oncology during the second quarter valued at about $63,000. Hedge funds and other institutional investors own 97.97% of the company's stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.